<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02101164</url>
  </required_header>
  <id_info>
    <org_study_id>20120127</org_study_id>
    <nct_id>NCT02101164</nct_id>
  </id_info>
  <brief_title>Evaluate Time Associated With the Preparation &amp; Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease</brief_title>
  <official_title>An Open-Label, Multicentre Trial to Evaluate the Time Associated With the Preparation and Administration of Denosumab and Pamidronate in Subjects With Solid Tumors and Metastatic Bone Disease in Canada</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will estimate the total time for the preparation and administration of denosumab
      and the total time for the preparation and administration of pamidronate.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total duration (in hours, minutes and seconds) for investigational product preparation and administration</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total duration (in hours, minutes and seconds) for investigational product preparation and administration</measure>
    <time_frame>Week 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total duration (in hours, minutes and seconds) for investigational product preparation and administration</measure>
    <time_frame>Week 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total duration (in hours, minutes and seconds) for investigational product preparation and administration</measure>
    <time_frame>Week 13</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Metastatic Bone Disease</condition>
  <arm_group>
    <arm_group_label>Treatment Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of denosumab every 4 weeks for 2 doses, followed by 1 dose of pamidronate every 4 weeks for 2 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of pamidronate every 4 weeks for 2 doses, followed by 1 dose of denosumab every 4 weeks for 2 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>denosumab</intervention_name>
    <description>Treatment Group A - 120 mg SC dose every 4 weeks at Day 1 and week 5 Treatment Group B - 120 mg SC dose every 4 weeks at Week 9 and Week 13</description>
    <arm_group_label>Treatment Group A</arm_group_label>
    <arm_group_label>Treatment Group B</arm_group_label>
    <other_name>XGEVA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pamidronate</intervention_name>
    <description>Treatment Group A - 90 mg IV dose every 4 weeks at Week 9 and Week 13 Treatment Group B - 90 mg IV dose every 4 weeks at Day 1 and Week 5</description>
    <arm_group_label>Treatment Group A</arm_group_label>
    <arm_group_label>Treatment Group B</arm_group_label>
    <other_name>Aredia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of metastatic bone disease secondary to a solid tumor (eg, breast cancer,
             lung cancer, etc).

          -  An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Subject is one of the following:

               -  being considered for pamidronate IV infusions or denosumab SC injections for
                  treatment of metastatic bone disease (prescribed per Canadian product monograph);
                  OR

               -  scheduled to receive pamidronate IV infusions or denosumab SC injections for
                  treatment of metastatic bone disease (prescribed per Canadian product monograph);
                  OR

               -  currently receiving pamidronate IV infusions or denosumab SC injections for
                  treatment of metastatic bone disease AND has received no more than 4 prior
                  administration of either product combined (prescribed per Canadian product
                  monograph).

          -  Subject has a serum calcium or albumin-adjusted serum calcium ≥ 2.0 mmol/L (8.0 mg/dL)
             and ≤ 2.9 mmol/L (11.5 mg/dL)

        Exclusion Criteria:

          -  Diagnosis with metastatic bone disease secondary to multiple myeloma or prostate
             cancer.

          -  Severe renal impairment (creatinine clearance &lt; 30 mL/min)

          -  Subject is being considered for ambulatory pamidronate administration using an infuser
             device (ie, &quot;baby bottle&quot;).

          -  A known active infection with Hepatitis B virus or Hepatitis C virus.

          -  Subject has known positive results for human immunodeficiency virus (HIV).Subject has
             a history of other malignancy within the past 5 years, other than:

               -  Malignancy treated with curative intent and with no known active disease present
                  for ≥ 5 years before enrollment and felt to be at low risk for recurrence by the
                  treating physician

               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
                  of disease

               -  Adequately treated cervical carcinoma in situ without evidence of disease

               -  Adequately treated breast ductal carcinoma in situ without evidence of disease

               -  Prostatic intraepithelial neoplasia without evidence of prostate cancer

               -  Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in
                  situ.

          -  Subject has a history or current evidence of osteonecrosis/osteomyelitis of the jaw,
             active dental or jaw condition that requires oral surgery, non-healed dental/oral
             surgery, or planned invasive dental procedure over the course of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2014</study_first_submitted>
  <study_first_submitted_qc>March 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2014</study_first_posted>
  <last_update_submitted>February 16, 2015</last_update_submitted>
  <last_update_submitted_qc>February 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

